BioNTech (NASDAQ:BNTX) Price Target Lowered to $130.00 at Bank of America

Key Points

• BioNTech's price target has been lowered by Bank of America from $134.00 to $130.00, maintaining a "buy" rating with a potential upside of 24.42% from the current price.
• Other analysts show a mixed sentiment; Weiss Ratings issued a "sell" rating, while Wells Fargo set a price target of $150.00 with an "overweight" rating.
• BioNTech's recent earnings report revealed a significant revenue increase of 102.6% year-over-year, despite reporting a loss of ($1.60) per share, missing consensus estimates.

BioNTech (NASDAQ:BNTX - Get Free Report) had its price target cut by equities researchers at Bank of America from $134.00 to $130.00 in a research note issued to investors on Wednesday,MarketScreener reports. The firm currently has a "buy" rating on the stock. Bank of America's target price indicates a potential upside of 24.42% from the company's current price.

Several other analysts have also recently commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a research report on Tuesday, October 14th. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an "overweight" rating in a report on Tuesday, August 5th. HC Wainwright reaffirmed a "buy" rating and issued a $136.00 target price on shares of BioNTech in a report on Monday, September 8th. JPMorgan Chase & Co. lifted their target price on shares of BioNTech from $116.00 to $121.00 and gave the company a "neutral" rating in a research report on Monday, September 22nd. Finally, Morgan Stanley dropped their price objective on shares of BioNTech from $133.00 to $131.00 and set an "overweight" rating for the company in a report on Friday, October 10th. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and a consensus price target of $134.03.

BioNTech Stock Performance

BioNTech stock opened at $104.49 on Wednesday. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. BioNTech has a 52 week low of $81.20 and a 52 week high of $129.27. The stock has a 50 day moving average of $103.52 and a 200-day moving average of $104.21. The stock has a market cap of $25.12 billion, a P/E ratio of -65.48 and a beta of 1.45.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. During the same period in the prior year, the firm earned ($3.36) earnings per share. The firm's quarterly revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. On average, analysts expect that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Trading of BioNTech

Large investors have recently made changes to their positions in the company. Rhenman & Partners Asset Management AB lifted its position in shares of BioNTech by 0.3% in the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company's stock valued at $3,819,000 after buying an additional 120 shares during the last quarter. Kennedy Capital Management LLC increased its stake in shares of BioNTech by 0.8% in the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company's stock valued at $1,748,000 after purchasing an additional 127 shares during the last quarter. Profund Advisors LLC raised its stake in BioNTech by 3.6% during the second quarter. Profund Advisors LLC now owns 4,309 shares of the company's stock worth $459,000 after acquiring an additional 149 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in BioNTech by 2.5% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company's stock valued at $822,000 after purchasing an additional 186 shares during the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in shares of BioNTech by 5.2% during the second quarter. SBI Securities Co. Ltd. now owns 3,865 shares of the company's stock valued at $412,000 after purchasing an additional 192 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.